Shannon L. Winski

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 465 citations

Medicine, Pharmacology, Pharmacotherapy +7

Selective RET kinase inhibition for patients with RET-altered cancers

Vivek Subbiah, Vamsidhar Velcheti, Brian B. Tuch et al. · Annals of Oncology · 2018 · 422 citations · Full text

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake et al. · Cancer Discovery · 2017 · 419 citations · Full text

Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H

David Siegel, Susan M. McGuinness, Shannon L. Winski et al. · Pharmacogenetics · 1999 · 238 citations

Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1

David J. Siegel, Adil Anwar, Shannon L. Winski et al. · Molecular Pharmacology · 2001 · 208 citations